Characteristics and Treatment Outcomes of Isoniazid Mono-Resistant Tuberculosis: A Retrospective Study
Purpose: Isoniazid (INH) mono-resistant tuberculosis (Hr-TB) is a highly prevalent type of drug-resistant TB, possibly associated with unfavorable treatment outcomes. However, definitive guidelines on an optimal treatment regimen and duration for Hr-TB are currently under discussion. We evaluated th...
Gespeichert in:
| Veröffentlicht in: | Yonsei medical journal 2020, 61(12), , pp.1034-1041 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1041 |
|---|---|
| container_issue | 12 |
| container_start_page | 1034 |
| container_title | Yonsei medical journal |
| container_volume | 61 |
| creator | Kwak, Se Hyun Choi, Ji Soo Lee, Eun Hye Lee, Su Hwan Leem, Ah Young Lee, Sang Hoon Kim, Song Yee Chung, Kyung Soo Kim, Eun Young Jung, Ji Ye Park, Moo Suk Kim, Young Sam Chang, Joon Kang, Young Ae |
| description | Purpose: Isoniazid (INH) mono-resistant tuberculosis (Hr-TB) is a highly prevalent type of drug-resistant TB, possibly associated with unfavorable treatment outcomes. However, definitive guidelines on an optimal treatment regimen and duration for Hr-TB are currently under discussion. We evaluated the characteristics and treatment outcomes of Hr-TB patients.
Materials and Methods: We retrospectively reviewed the medical records of Hr-TB patients treated at a South Korean tertiary referral hospital from January 2005 to December 2018.
Results: We included 195 Hr-TB patients. 113 (57.9%) were male, and the median age was 56.6 [interquartile range, 40.2-68.6] years. Mutations in katG were the most frequent [54 (56.3%)], followed by those in the inhA [34 (35.4%)]. Favorable and unfavorable outcomes were noted in 164 (84.1%) and 31 (15.9%) patients, respectively. Smoking history [odds ratio (OR)=5.606, 95% confidence interval (CI): 1.695-18.543, p=0.005], low albumin level (OR=0.246, 95% CI: 0.104-0.578, p=0.001), and positive acid-fast bacilli culture at 2 months (OR=7.853, 95% CI: 1.246-49.506, p=0.028) were associated with unfavorable outcomes.
Conclusion: A tailored strategy targeting high-risk patients is imperative for improved treatment outcomes. Further research on the rapid and accurate detection of resistance to INH and other companion drugs is warranted. |
| doi_str_mv | 10.3349/ymj.2020.61.12.1034 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_webofscience_primary_000595535600006</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2465755412</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-d443bf705e6452af1159a65da3f9bf920aa2d920534e9b253196ba81a27fad4f3</originalsourceid><addsrcrecordid>eNqNkV1v0zAYhSMEYmXwC5BQLkEowd-uuUCqIj4qDU0q5dpyHJt5S-zOdobKr8ddRwV3XB3Lfs55bZ-qeglBizER7_bTdYsAAi2DLUQtBJg8qhZQcNYggvnjagEoxA3lgp1Vz1K6BgBxCNDT6gxjRCHnfFHZ7kpFpbOJLmWnU638UG-jUXkyPteXc9ZhMqkOtl6n4J365Yb6a_Ch2ZhULKpA27k3Uc9jKBvv61W9MTmGtDM6uztTf8vzsH9ePbFqTObFg55X3z993HZfmovLz-tuddFogkVuBkJwbzmghhGKlIWQCsXooLAVvRUIKIWGIhQTI3pEMRSsV0uoELdqIBafV2-OuT5aeaOdDMrd648gb6JcbbZrKRjgiC0L--HI7uZ-MoMu741qlLvoJhX3985_T7y7Kjl3knMAlpyWgNcPATHcziZlObmkzTgqb8KcJCKMckoJRAXFR1SXn0nR2NMYCOShTVnalIc2JYMSInlos7he_X3Dk-dPfQV4ewR-mj7YpJ3x2pwwAAAVlGLKygqwQi__n-5cVtkF34XZZ_wbMsO-lw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2465755412</pqid></control><display><type>article</type><title>Characteristics and Treatment Outcomes of Isoniazid Mono-Resistant Tuberculosis: A Retrospective Study</title><source>KoreaMed Synapse</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>KoreaMed Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Kwak, Se Hyun ; Choi, Ji Soo ; Lee, Eun Hye ; Lee, Su Hwan ; Leem, Ah Young ; Lee, Sang Hoon ; Kim, Song Yee ; Chung, Kyung Soo ; Kim, Eun Young ; Jung, Ji Ye ; Park, Moo Suk ; Kim, Young Sam ; Chang, Joon ; Kang, Young Ae</creator><creatorcontrib>Kwak, Se Hyun ; Choi, Ji Soo ; Lee, Eun Hye ; Lee, Su Hwan ; Leem, Ah Young ; Lee, Sang Hoon ; Kim, Song Yee ; Chung, Kyung Soo ; Kim, Eun Young ; Jung, Ji Ye ; Park, Moo Suk ; Kim, Young Sam ; Chang, Joon ; Kang, Young Ae</creatorcontrib><description>Purpose: Isoniazid (INH) mono-resistant tuberculosis (Hr-TB) is a highly prevalent type of drug-resistant TB, possibly associated with unfavorable treatment outcomes. However, definitive guidelines on an optimal treatment regimen and duration for Hr-TB are currently under discussion. We evaluated the characteristics and treatment outcomes of Hr-TB patients.
Materials and Methods: We retrospectively reviewed the medical records of Hr-TB patients treated at a South Korean tertiary referral hospital from January 2005 to December 2018.
Results: We included 195 Hr-TB patients. 113 (57.9%) were male, and the median age was 56.6 [interquartile range, 40.2-68.6] years. Mutations in katG were the most frequent [54 (56.3%)], followed by those in the inhA [34 (35.4%)]. Favorable and unfavorable outcomes were noted in 164 (84.1%) and 31 (15.9%) patients, respectively. Smoking history [odds ratio (OR)=5.606, 95% confidence interval (CI): 1.695-18.543, p=0.005], low albumin level (OR=0.246, 95% CI: 0.104-0.578, p=0.001), and positive acid-fast bacilli culture at 2 months (OR=7.853, 95% CI: 1.246-49.506, p=0.028) were associated with unfavorable outcomes.
Conclusion: A tailored strategy targeting high-risk patients is imperative for improved treatment outcomes. Further research on the rapid and accurate detection of resistance to INH and other companion drugs is warranted.</description><identifier>ISSN: 0513-5796</identifier><identifier>EISSN: 1976-2437</identifier><identifier>DOI: 10.3349/ymj.2020.61.12.1034</identifier><identifier>PMID: 33251777</identifier><language>eng</language><publisher>SEOUL: Yonsei Univ Coll Medicine</publisher><subject>Adult ; Aged ; Antitubercular Agents - pharmacology ; Antitubercular Agents - therapeutic use ; Female ; General & Internal Medicine ; Humans ; Isoniazid - pharmacology ; Isoniazid - therapeutic use ; Life Sciences & Biomedicine ; Male ; Medicine, General & Internal ; Middle Aged ; Mutation ; Mycobacterium tuberculosis - drug effects ; Mycobacterium tuberculosis - genetics ; Mycobacterium tuberculosis - isolation & purification ; Original ; Prevalence ; Republic of Korea - epidemiology ; Retrospective Studies ; Science & Technology ; Treatment Outcome ; Tuberculosis - drug therapy ; Tuberculosis, Multidrug-Resistant - drug therapy ; 의학일반</subject><ispartof>Yonsei Medical Journal, 2020, 61(12), , pp.1034-1041</ispartof><rights>Copyright: Yonsei University College of Medicine 2020.</rights><rights>Copyright: Yonsei University College of Medicine 2020 2020 Yonsei University College of Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>8</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000595535600006</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c439t-d443bf705e6452af1159a65da3f9bf920aa2d920534e9b253196ba81a27fad4f3</citedby><cites>FETCH-LOGICAL-c439t-d443bf705e6452af1159a65da3f9bf920aa2d920534e9b253196ba81a27fad4f3</cites><orcidid>0000-0002-3281-5744 ; 0000-0002-5680-111X ; 0000-0003-1604-8730 ; 0000-0002-7783-5271 ; 0000-0003-2570-3442 ; 0000-0003-4542-6841 ; 0000-0001-9656-8482 ; 0000-0001-5165-3704 ; 0000-0003-1589-4142 ; 0000-0002-7706-5318 ; 0000-0001-8627-486X ; 0000-0003-0820-7615 ; 0000-0003-2716-6775 ; 0000-0002-3487-2574</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700875/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700875/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2115,27928,27929,53795,53797</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33251777$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002648301$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Kwak, Se Hyun</creatorcontrib><creatorcontrib>Choi, Ji Soo</creatorcontrib><creatorcontrib>Lee, Eun Hye</creatorcontrib><creatorcontrib>Lee, Su Hwan</creatorcontrib><creatorcontrib>Leem, Ah Young</creatorcontrib><creatorcontrib>Lee, Sang Hoon</creatorcontrib><creatorcontrib>Kim, Song Yee</creatorcontrib><creatorcontrib>Chung, Kyung Soo</creatorcontrib><creatorcontrib>Kim, Eun Young</creatorcontrib><creatorcontrib>Jung, Ji Ye</creatorcontrib><creatorcontrib>Park, Moo Suk</creatorcontrib><creatorcontrib>Kim, Young Sam</creatorcontrib><creatorcontrib>Chang, Joon</creatorcontrib><creatorcontrib>Kang, Young Ae</creatorcontrib><title>Characteristics and Treatment Outcomes of Isoniazid Mono-Resistant Tuberculosis: A Retrospective Study</title><title>Yonsei medical journal</title><addtitle>YONSEI MED J</addtitle><addtitle>Yonsei Med J</addtitle><description>Purpose: Isoniazid (INH) mono-resistant tuberculosis (Hr-TB) is a highly prevalent type of drug-resistant TB, possibly associated with unfavorable treatment outcomes. However, definitive guidelines on an optimal treatment regimen and duration for Hr-TB are currently under discussion. We evaluated the characteristics and treatment outcomes of Hr-TB patients.
Materials and Methods: We retrospectively reviewed the medical records of Hr-TB patients treated at a South Korean tertiary referral hospital from January 2005 to December 2018.
Results: We included 195 Hr-TB patients. 113 (57.9%) were male, and the median age was 56.6 [interquartile range, 40.2-68.6] years. Mutations in katG were the most frequent [54 (56.3%)], followed by those in the inhA [34 (35.4%)]. Favorable and unfavorable outcomes were noted in 164 (84.1%) and 31 (15.9%) patients, respectively. Smoking history [odds ratio (OR)=5.606, 95% confidence interval (CI): 1.695-18.543, p=0.005], low albumin level (OR=0.246, 95% CI: 0.104-0.578, p=0.001), and positive acid-fast bacilli culture at 2 months (OR=7.853, 95% CI: 1.246-49.506, p=0.028) were associated with unfavorable outcomes.
Conclusion: A tailored strategy targeting high-risk patients is imperative for improved treatment outcomes. Further research on the rapid and accurate detection of resistance to INH and other companion drugs is warranted.</description><subject>Adult</subject><subject>Aged</subject><subject>Antitubercular Agents - pharmacology</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>Female</subject><subject>General & Internal Medicine</subject><subject>Humans</subject><subject>Isoniazid - pharmacology</subject><subject>Isoniazid - therapeutic use</subject><subject>Life Sciences & Biomedicine</subject><subject>Male</subject><subject>Medicine, General & Internal</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Mycobacterium tuberculosis - drug effects</subject><subject>Mycobacterium tuberculosis - genetics</subject><subject>Mycobacterium tuberculosis - isolation & purification</subject><subject>Original</subject><subject>Prevalence</subject><subject>Republic of Korea - epidemiology</subject><subject>Retrospective Studies</subject><subject>Science & Technology</subject><subject>Treatment Outcome</subject><subject>Tuberculosis - drug therapy</subject><subject>Tuberculosis, Multidrug-Resistant - drug therapy</subject><subject>의학일반</subject><issn>0513-5796</issn><issn>1976-2437</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><recordid>eNqNkV1v0zAYhSMEYmXwC5BQLkEowd-uuUCqIj4qDU0q5dpyHJt5S-zOdobKr8ddRwV3XB3Lfs55bZ-qeglBizER7_bTdYsAAi2DLUQtBJg8qhZQcNYggvnjagEoxA3lgp1Vz1K6BgBxCNDT6gxjRCHnfFHZ7kpFpbOJLmWnU638UG-jUXkyPteXc9ZhMqkOtl6n4J365Yb6a_Ch2ZhULKpA27k3Uc9jKBvv61W9MTmGtDM6uztTf8vzsH9ePbFqTObFg55X3z993HZfmovLz-tuddFogkVuBkJwbzmghhGKlIWQCsXooLAVvRUIKIWGIhQTI3pEMRSsV0uoELdqIBafV2-OuT5aeaOdDMrd648gb6JcbbZrKRjgiC0L--HI7uZ-MoMu741qlLvoJhX3985_T7y7Kjl3knMAlpyWgNcPATHcziZlObmkzTgqb8KcJCKMckoJRAXFR1SXn0nR2NMYCOShTVnalIc2JYMSInlos7he_X3Dk-dPfQV4ewR-mj7YpJ3x2pwwAAAVlGLKygqwQi__n-5cVtkF34XZZ_wbMsO-lw</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Kwak, Se Hyun</creator><creator>Choi, Ji Soo</creator><creator>Lee, Eun Hye</creator><creator>Lee, Su Hwan</creator><creator>Leem, Ah Young</creator><creator>Lee, Sang Hoon</creator><creator>Kim, Song Yee</creator><creator>Chung, Kyung Soo</creator><creator>Kim, Eun Young</creator><creator>Jung, Ji Ye</creator><creator>Park, Moo Suk</creator><creator>Kim, Young Sam</creator><creator>Chang, Joon</creator><creator>Kang, Young Ae</creator><general>Yonsei Univ Coll Medicine</general><general>Yonsei University College of Medicine</general><general>연세대학교의과대학</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ACYCR</scope><orcidid>https://orcid.org/0000-0002-3281-5744</orcidid><orcidid>https://orcid.org/0000-0002-5680-111X</orcidid><orcidid>https://orcid.org/0000-0003-1604-8730</orcidid><orcidid>https://orcid.org/0000-0002-7783-5271</orcidid><orcidid>https://orcid.org/0000-0003-2570-3442</orcidid><orcidid>https://orcid.org/0000-0003-4542-6841</orcidid><orcidid>https://orcid.org/0000-0001-9656-8482</orcidid><orcidid>https://orcid.org/0000-0001-5165-3704</orcidid><orcidid>https://orcid.org/0000-0003-1589-4142</orcidid><orcidid>https://orcid.org/0000-0002-7706-5318</orcidid><orcidid>https://orcid.org/0000-0001-8627-486X</orcidid><orcidid>https://orcid.org/0000-0003-0820-7615</orcidid><orcidid>https://orcid.org/0000-0003-2716-6775</orcidid><orcidid>https://orcid.org/0000-0002-3487-2574</orcidid></search><sort><creationdate>20201201</creationdate><title>Characteristics and Treatment Outcomes of Isoniazid Mono-Resistant Tuberculosis: A Retrospective Study</title><author>Kwak, Se Hyun ; Choi, Ji Soo ; Lee, Eun Hye ; Lee, Su Hwan ; Leem, Ah Young ; Lee, Sang Hoon ; Kim, Song Yee ; Chung, Kyung Soo ; Kim, Eun Young ; Jung, Ji Ye ; Park, Moo Suk ; Kim, Young Sam ; Chang, Joon ; Kang, Young Ae</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-d443bf705e6452af1159a65da3f9bf920aa2d920534e9b253196ba81a27fad4f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antitubercular Agents - pharmacology</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>Female</topic><topic>General & Internal Medicine</topic><topic>Humans</topic><topic>Isoniazid - pharmacology</topic><topic>Isoniazid - therapeutic use</topic><topic>Life Sciences & Biomedicine</topic><topic>Male</topic><topic>Medicine, General & Internal</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Mycobacterium tuberculosis - drug effects</topic><topic>Mycobacterium tuberculosis - genetics</topic><topic>Mycobacterium tuberculosis - isolation & purification</topic><topic>Original</topic><topic>Prevalence</topic><topic>Republic of Korea - epidemiology</topic><topic>Retrospective Studies</topic><topic>Science & Technology</topic><topic>Treatment Outcome</topic><topic>Tuberculosis - drug therapy</topic><topic>Tuberculosis, Multidrug-Resistant - drug therapy</topic><topic>의학일반</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kwak, Se Hyun</creatorcontrib><creatorcontrib>Choi, Ji Soo</creatorcontrib><creatorcontrib>Lee, Eun Hye</creatorcontrib><creatorcontrib>Lee, Su Hwan</creatorcontrib><creatorcontrib>Leem, Ah Young</creatorcontrib><creatorcontrib>Lee, Sang Hoon</creatorcontrib><creatorcontrib>Kim, Song Yee</creatorcontrib><creatorcontrib>Chung, Kyung Soo</creatorcontrib><creatorcontrib>Kim, Eun Young</creatorcontrib><creatorcontrib>Jung, Ji Ye</creatorcontrib><creatorcontrib>Park, Moo Suk</creatorcontrib><creatorcontrib>Kim, Young Sam</creatorcontrib><creatorcontrib>Chang, Joon</creatorcontrib><creatorcontrib>Kang, Young Ae</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Korean Citation Index</collection><jtitle>Yonsei medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kwak, Se Hyun</au><au>Choi, Ji Soo</au><au>Lee, Eun Hye</au><au>Lee, Su Hwan</au><au>Leem, Ah Young</au><au>Lee, Sang Hoon</au><au>Kim, Song Yee</au><au>Chung, Kyung Soo</au><au>Kim, Eun Young</au><au>Jung, Ji Ye</au><au>Park, Moo Suk</au><au>Kim, Young Sam</au><au>Chang, Joon</au><au>Kang, Young Ae</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characteristics and Treatment Outcomes of Isoniazid Mono-Resistant Tuberculosis: A Retrospective Study</atitle><jtitle>Yonsei medical journal</jtitle><stitle>YONSEI MED J</stitle><addtitle>Yonsei Med J</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>61</volume><issue>12</issue><spage>1034</spage><epage>1041</epage><pages>1034-1041</pages><issn>0513-5796</issn><eissn>1976-2437</eissn><abstract>Purpose: Isoniazid (INH) mono-resistant tuberculosis (Hr-TB) is a highly prevalent type of drug-resistant TB, possibly associated with unfavorable treatment outcomes. However, definitive guidelines on an optimal treatment regimen and duration for Hr-TB are currently under discussion. We evaluated the characteristics and treatment outcomes of Hr-TB patients.
Materials and Methods: We retrospectively reviewed the medical records of Hr-TB patients treated at a South Korean tertiary referral hospital from January 2005 to December 2018.
Results: We included 195 Hr-TB patients. 113 (57.9%) were male, and the median age was 56.6 [interquartile range, 40.2-68.6] years. Mutations in katG were the most frequent [54 (56.3%)], followed by those in the inhA [34 (35.4%)]. Favorable and unfavorable outcomes were noted in 164 (84.1%) and 31 (15.9%) patients, respectively. Smoking history [odds ratio (OR)=5.606, 95% confidence interval (CI): 1.695-18.543, p=0.005], low albumin level (OR=0.246, 95% CI: 0.104-0.578, p=0.001), and positive acid-fast bacilli culture at 2 months (OR=7.853, 95% CI: 1.246-49.506, p=0.028) were associated with unfavorable outcomes.
Conclusion: A tailored strategy targeting high-risk patients is imperative for improved treatment outcomes. Further research on the rapid and accurate detection of resistance to INH and other companion drugs is warranted.</abstract><cop>SEOUL</cop><pub>Yonsei Univ Coll Medicine</pub><pmid>33251777</pmid><doi>10.3349/ymj.2020.61.12.1034</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-3281-5744</orcidid><orcidid>https://orcid.org/0000-0002-5680-111X</orcidid><orcidid>https://orcid.org/0000-0003-1604-8730</orcidid><orcidid>https://orcid.org/0000-0002-7783-5271</orcidid><orcidid>https://orcid.org/0000-0003-2570-3442</orcidid><orcidid>https://orcid.org/0000-0003-4542-6841</orcidid><orcidid>https://orcid.org/0000-0001-9656-8482</orcidid><orcidid>https://orcid.org/0000-0001-5165-3704</orcidid><orcidid>https://orcid.org/0000-0003-1589-4142</orcidid><orcidid>https://orcid.org/0000-0002-7706-5318</orcidid><orcidid>https://orcid.org/0000-0001-8627-486X</orcidid><orcidid>https://orcid.org/0000-0003-0820-7615</orcidid><orcidid>https://orcid.org/0000-0003-2716-6775</orcidid><orcidid>https://orcid.org/0000-0002-3487-2574</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0513-5796 |
| ispartof | Yonsei Medical Journal, 2020, 61(12), , pp.1034-1041 |
| issn | 0513-5796 1976-2437 |
| language | eng |
| recordid | cdi_webofscience_primary_000595535600006 |
| source | KoreaMed Synapse; MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central Open Access; KoreaMed Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adult Aged Antitubercular Agents - pharmacology Antitubercular Agents - therapeutic use Female General & Internal Medicine Humans Isoniazid - pharmacology Isoniazid - therapeutic use Life Sciences & Biomedicine Male Medicine, General & Internal Middle Aged Mutation Mycobacterium tuberculosis - drug effects Mycobacterium tuberculosis - genetics Mycobacterium tuberculosis - isolation & purification Original Prevalence Republic of Korea - epidemiology Retrospective Studies Science & Technology Treatment Outcome Tuberculosis - drug therapy Tuberculosis, Multidrug-Resistant - drug therapy 의학일반 |
| title | Characteristics and Treatment Outcomes of Isoniazid Mono-Resistant Tuberculosis: A Retrospective Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T08%3A09%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characteristics%20and%20Treatment%20Outcomes%20of%20Isoniazid%20Mono-Resistant%20Tuberculosis:%20A%20Retrospective%20Study&rft.jtitle=Yonsei%20medical%20journal&rft.au=Kwak,%20Se%20Hyun&rft.date=2020-12-01&rft.volume=61&rft.issue=12&rft.spage=1034&rft.epage=1041&rft.pages=1034-1041&rft.issn=0513-5796&rft.eissn=1976-2437&rft_id=info:doi/10.3349/ymj.2020.61.12.1034&rft_dat=%3Cproquest_webof%3E2465755412%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2465755412&rft_id=info:pmid/33251777&rfr_iscdi=true |